Ocular Side Effects of Bisphosphonates: A Review of Literature
Journal of Ocular Pharmacology and Therapeutics · 01.02.2023 · 39 (1) · 3-16
DOI: 10.1089/jop.2022.0094 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Ocular Pharmacology and Therapeutics, online erschienen am 25.01.2023. Verfasst von Nicholas A Chartrand und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine Phoenix, University of Arizona, Phoenix, Arizona, USA. Hauptthemen laut MEDLINE: Bone Density Conservation Agents, Drug-Related Side Effects and Adverse Reactions, Scleritis. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 151 Literaturangaben.
Abstract (Originalsprache)
In rare cases, bisphosphonates are well established to cause ocular inflammation, presenting as uveitis, episcleritis, scleritis, orbital inflammation, and/or conjunctivitis. Some reports of bisphosphonate-associated neuro-ophthalmic complications also exist. We identified 101 reports in the literature relating to bisphosphonate-associated ocular complications. In a great majority of cases, symptoms resolve after discontinuation of the drug and anti-inflammatory treatment. Many cases recur if rechallenged with the same bisphosphonate. First-generation nonamino bisphosphonates, including clodronate and etidronate, are not associated with ocular inflammation. Only 2nd- and 3rd-generation amino bisphosphonates, including pamidronate, alendronate, risedronate, ibandronate, and zoledronate are associated with these complications. The mechanism of bisphosphonate-induced ocular inflammation may be related to activation of γ/δ T cells or M1 macrophages. Intravenous forms, such as pamidronate and zoledronate, tend to have higher rates and faster onset of ocular inflammation, generally presenting within days of infusion. In oral bisphosphonates, such as alendronate and risedronate, these complications present with more sporadic timing. Rates of complications are also higher when bisphosphonates are used for malignancy, as doses tend to be higher compared with doses for osteoporosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Medicine Phoenix, University of Arizona, Phoenix, Arizona, USA.
- Hoopes Vision Research Center, Hoopes Vision, Draper, Utah, USA.
- Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah School of Medicine, Salt Lake City, Utah, USA.
- Utah Lions Eye Bank, Murray, Utah, USA.
ORCID-Profile: Nicholas A Chartrand, Chap-Kay Lau, Mark T Parsons, Jaiden J Handlon, Yasmyne C Ronquillo, Majid Moshirfar
Zitieren
APA
Chartrand, N. A., Lau, C. K., Parsons, M. T., Handlon, J. J., Ronquillo, Y. C., Hoopes, P. C., & Moshirfar, M. (2023). Ocular Side Effects of Bisphosphonates: A Review of Literature. Journal of Ocular Pharmacology and Therapeutics, 39(1), 3-16. https://doi.org/10.1089/jop.2022.0094
Vancouver
Chartrand NA, Lau CK, Parsons MT, Handlon JJ, Ronquillo YC, Hoopes PC, et al. Ocular Side Effects of Bisphosphonates: A Review of Literature. Journal of Ocular Pharmacology and Therapeutics. 2023;39(1):3-16. doi:10.1089/jop.2022.0094
BibTeX
@article{Chartrand2023,
author = {Chartrand, Nicholas A and Lau, Chap-Kay and Parsons, Mark T and Handlon, Jaiden J and Ronquillo, Yasmyne C and Hoopes, Phillip C and Moshirfar, Majid},
title = {Ocular Side Effects of Bisphosphonates: A Review of Literature},
journal = {Journal of Ocular Pharmacology and Therapeutics},
year = {2023},
volume = {39},
number = {1},
pages = {3--16},
doi = {10.1089/jop.2022.0094}
}
EUVIMED